These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

374 related items for PubMed ID: 1617314

  • 1. Treatment of infant leukemia with busulfan, cyclophosphamide +/- etoposide and bone marrow transplantation.
    Emminger W, Emminger-Schmidmeier W, Haas OA, Urban C, Ambros P, Peters C, Mann G, Fink FM, Ferstl G, Höcker P.
    Bone Marrow Transplant; 1992 May; 9(5):313-8. PubMed ID: 1617314
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Bone marrow transplantation for advanced acute leukemia: a pilot study of high-energy total body irradiation, cyclophosphamide and continuous infusion etoposide.
    Bostrom B, Weisdorf DJ, Kim T, Kersey JH, Ramsay NK.
    Bone Marrow Transplant; 1990 Feb; 5(2):83-9. PubMed ID: 2107007
    [Abstract] [Full Text] [Related]

  • 4. Improved results of allogeneic bone marrow transplantation for advanced hematologic malignancy using busulfan, cyclophosphamide and etoposide as cytoreductive and immunosuppressive therapy.
    Vaughan WP, Dennison JD, Reed EC, Klassen L, McGuire TR, Sanger WG, Kumar PP, Warkentin PI, Gordon BG, Bierman PJ.
    Bone Marrow Transplant; 1991 Dec; 8(6):489-95. PubMed ID: 1790429
    [Abstract] [Full Text] [Related]

  • 5. Allogeneic bone marrow transplantation for childhood leukemia following a busulfan and melphalan preparative regimen.
    Matsuyama T, Kojima S, Kato K.
    Bone Marrow Transplant; 1998 Jul; 22(1):21-6. PubMed ID: 9678791
    [Abstract] [Full Text] [Related]

  • 6. Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies.
    Long GD, Amylon MD, Stockerl-Goldstein KE, Negrin RS, Chao NJ, Hu WW, Nademanee AP, Snyder DS, Hoppe RT, Vora N, Wong R, Niland J, Reichardt VL, Forman SJ, Blume KG.
    Biol Blood Marrow Transplant; 1997 Dec; 3(6):324-30. PubMed ID: 9502300
    [Abstract] [Full Text] [Related]

  • 7. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A, Iori A, Guglielmi C, Romano A, Cerretti R, Torromeo C, Micozzi A, Fenu S, Laurenti L, Donato V, De Felice L, Arcese W.
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [Abstract] [Full Text] [Related]

  • 8. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
    Kröger N, Zabelina T, Sonnenberg S, Krüger W, Renges H, Stute N, Finkenstein F, Mayer U, Holstein K, Fiedler W, Colberg H, Sonnen R, Kuse R, Braumann D, Metzner B, del Valle F, Erttmann R, Kabisch H, Zander AR.
    Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
    [Abstract] [Full Text] [Related]

  • 9. High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.
    Zander AR, Berger C, Kröger N, Stockshläder M, Krüger W, Horstmann M, Grimm J, Zeller W, Kabisch H, Erttmann R, Schönrock P, Kuse R, Braumann D, Illiger HJ, Fiedler W, de Witt M, Hossfeld KD, Weh HJ.
    Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2671-5. PubMed ID: 10068272
    [Abstract] [Full Text] [Related]

  • 10. CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens.
    Kalaycio M, Rybicki L, Pohlman B, Sobecks R, Ball E, Cook D, Andresen S, Kuczkowski E, Bolwell B.
    Bone Marrow Transplant; 2005 Feb; 35(3):247-52. PubMed ID: 15580282
    [Abstract] [Full Text] [Related]

  • 11. Allogeneic bone marrow transplantation for acute myelogenous leukemia, acute lymphocytic leukemia, and multiple myeloma following preparation with busulfan and cyclophosphamide (BuCy2).
    Copelan EA, Biggs JC, Szer J, Thompson JM, Crilley P, Brodsky I, Klein JL, Kapoor N, Harman GS, Avalos BR.
    Semin Oncol; 1993 Aug; 20(4 Suppl 4):33-8; quiz 39. PubMed ID: 8342074
    [Abstract] [Full Text] [Related]

  • 12. Allogeneic bone marrow transplantation following a busulfan-based conditioning regimen in young children with acute lymphoblastic leukemia: a Cooperative Study of the Société Française de Greffe de Moelle.
    von Bueltzingsloewen A, Esperou-Bourdeau H, Souillet G, Demeocq F, Mechinaud-Lacroix F, Michel G, Sadoun A, Bernaudin F, Cornu G, Donadieu J.
    Bone Marrow Transplant; 1995 Oct; 16(4):521-7. PubMed ID: 8528167
    [Abstract] [Full Text] [Related]

  • 13. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
    Sahebi F, Copelan E, Crilley P, Bolwell B, Avalos B, Klein J, Territo M, Gajewski J.
    Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
    [Abstract] [Full Text] [Related]

  • 14. Total body irradiation and high-dose cyclophosphamide, BCNU and VP-16 (CBV) as a new preparatory regimen for allogeneic bone marrow transplantation in patients with advanced hematologic malignancies.
    Wu DP, Milpied N, Moreau P, Mechinaud-Lacroix F, Mahe B, Le Tortorec S, Rapp MJ, Bourdin S, Mahe JM, Harousseau JL.
    Bone Marrow Transplant; 1994 Nov; 14(5):751-7. PubMed ID: 7889008
    [Abstract] [Full Text] [Related]

  • 15. [Second marrow transplantation following high dose busulfan, etoposide, and Ara-C after testicular relapse in a patient with AML].
    Matsue K, Tohi T, Masauji N, Tsukuda K.
    Rinsho Ketsueki; 1992 Mar; 33(3):338-42. PubMed ID: 1578638
    [Abstract] [Full Text] [Related]

  • 16. Allogeneic bone marrow transplantation for children with acute leukemia: cytoreduction with fractionated total body irradiation, high-dose etoposide and cyclophosphamide.
    Duerst RE, Horan JT, Liesveld JL, Abboud CN, Zwetsch LM, Senf ES, Constine LS, Raubertas RF, Passarell JA, DiPersio JF.
    Bone Marrow Transplant; 2000 Mar; 25(5):489-94. PubMed ID: 10713624
    [Abstract] [Full Text] [Related]

  • 17. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma.
    Hänel M, Kröger N, Sonnenberg S, Bornhäuser M, Krüger W, Kroschinsky F, Hänel A, Metzner B, Birkmann J, Schmid B, Hoffknecht MM, Fiedler F, Ehninger G, Zander AR.
    Ann Hematol; 2002 Feb; 81(2):96-102. PubMed ID: 11907790
    [Abstract] [Full Text] [Related]

  • 18. Allogeneic and autologous bone marrow transplantation after consolidation therapy in high-risk acute myeloid leukemia in children. Towards a risk-oriented therapy.
    Ortega JJ, Díaz de Heredia C, Olivé T, Bastida P, Llort A, Armadans L, Torrabadella M, Massuet L.
    Haematologica; 2003 Mar; 88(3):290-9. PubMed ID: 12651268
    [Abstract] [Full Text] [Related]

  • 19. Busulfan, cyclophosphamide and melphalan as conditioning regimen for bone marrow transplantation in children with myelodysplastic syndromes.
    Locatelli F, Pession A, Bonetti F, Maserati E, Prete L, Pedrazzoli P, Zecca M, Prete A, Paolucci P, Cazzola M.
    Leukemia; 1994 May; 8(5):844-9. PubMed ID: 8182940
    [Abstract] [Full Text] [Related]

  • 20. [Autologous bone marrow transplantation in children with acute leukemia or non-Hodgkin's lymphoma].
    Emminger W, Hinterberger W, Emminger-Schmidmeier W, Peters C, Fink FM, Zoubek A, Haas OA, Höcker P, Hawliczek R, Knapp W.
    Wien Med Wochenschr; 1991 May; 141(9-10):225-8. PubMed ID: 1683071
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.